-
公开(公告)号：US12209145B2
公开(公告)日：2025-01-28
申请号：US17854379
申请日：2022-06-30
Applicant: Merck Sharp & Dohme LLC
Inventor： Harold B. Wood , Hubert B. Josien , Thomas Joseph Tucker , Angela Dawn Kerekes , Ling Tong , Abbas M. Walji , Anilkumar G. Nair , Fa-Xiang Ding , Elisabetta Bianchi , Danila Branca , Chengwei Wu , Yusheng Xiong , Sookhee Nicole Ha , Jian Liu , Sobhana Babu Boga
Abstract: Disclosed are compounds of Formula I, or a salt thereof: where A, B, D, X, R1, R2 and R8 are as defined herein, which compounds have properties for antagonizing PCSK9. Also described are pharmaceutical formulations comprising the compounds of Formula I or their salts, and methods of treating cardiovascular disease and conditions related to PCSK9 activity, e.g. atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions.
-
公开(公告)号：US11427616B2
公开(公告)日：2022-08-30
申请号：US16446940
申请日：2019-06-20
Applicant: Merck Sharp & Dohme LLC
Inventor： Harold B. Wood , Hubert B. Josien , Thomas Joseph Tucker , Angela Dawn Kerekes , Ling Tong , Abbas M. Walji , Anilkumar G. Nair , Fa-Xiang Ding , Elisabetta Bianchi , Danila Branca , Chengwei Wu , Yusheng Xiong , Sookhee Nicole Ha , Jian Liu , Sobhana Babu Boga
Abstract: Disclosed are compounds of Formula I, or a salt thereof: where A, B, D, X, R1, R2 and R8 are as defined herein, which compounds have properties for antagonizing PCSK9. Also described are pharmaceutical formulations comprising the compounds of Formula I or their salts, and methods of treating cardiovascular disease and conditions related to PCSK9 activity, e.g. atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions.
-
公开(公告)号：US20240018140A1
公开(公告)日：2024-01-18
申请号：US18043385
申请日：2021-09-15
Applicant: Merck Sharp & Dohme LLC
Inventor： Melissa C. Ford , Mark E. Fraley , Kristen L.G. Jones , H. Marie Loughran , James J. Mulhearn , Anthony J. Roecker , Kathy M. Schirripa , Ling Tong
IPC: C07D471/04 , C07D519/00
CPC classification number: C07D471/04 , C07D519/00
Abstract: The present invention relates to Compounds of Formula I: I and pharmaceutically acceptable salts or prodrug thereof. The present invention also relates to compositions comprising at least one compound of Formula I, and methods of using the compounds of Formula I for treatment or prophylaxis of lysosomal storage diseases, neurodegenerative disease, cystic disease, cancer, or a diseases or disorders associated with elevated levels of glucosylceramide (GlcCer), glucosylsphingosine (GlcSph) and/or other glucosylceramide-based glycosphingolipids (GSLs).
-
公开(公告)号：US20250026762A1
公开(公告)日：2025-01-23
申请号：US18712270
申请日：2022-11-28
Applicant: Merck Sharp & Dohme LLC
Inventor： Mark E. Fraley , Tao Liang , H. Marie Loughran , Anthony J. Roecker , Kathy M. Schirripa , Ling Tong , Ashwin U. Rao
IPC: C07D487/08 , A61K31/551 , C07D519/00
Abstract: The present invention relates to Compounds of Formula (I) and pharmaceutically acceptable salts or prodrug thereof. The present invention also relates to compositions comprising at least one compound of Formula (I), and methods of using the compounds of Formula (I) for treatment or prophylaxis of lysosomal storage diseases, neurodegenerative disease, cystic disease, cancer, or a diseases or disorders associated with elevated levels of glucosylceramide (GlcCer), glucosylsphingosine (GlcSph) and/or other glucosylceramide-based glycosphingolipids (GSLs).
-
5.发明公开公开(公告)号：US20240083910A1
公开(公告)日：2024-03-14
申请号：US18257003
申请日：2021-12-14
Applicant: Richard BERGER , Christopher Douglas COX , Brendan M. CROWLEY , Marc LABROLI , Michael Aaron PLOTKIN , Izzat Tiedje RAHEEM , Deyou SHA , Anthony SHAW , Jason W. SKUDLAREK , Ling TONG , Merck Sharp & Dohme LLC
Inventor： Richard Thaddeus Berger, JR. , Christopher Douglas Cox , Brendan M. Crowley , Marc Labroli , Michael Aaron Plotkin , Izzat Tiedje Raheem , Deyou Sha , Anthony W. Shaw , Jason W. Skudlarek , Ling Tong
IPC: C07D498/04 , A61K31/444 , A61K31/496 , A61K31/4985 , A61K31/501 , A61K31/506 , A61K31/517 , A61P31/22 , C07D401/14 , C07D519/00
CPC classification number: C07D498/04 , A61K31/444 , A61K31/496 , A61K31/4985 , A61K31/501 , A61K31/506 , A61K31/517 , A61P31/22 , C07D401/14 , C07D519/00
Abstract: The present invention relates to novel Amido-Substituted Heterocycle Compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, and R5 are as defined herein. The present invention also relates to compositions comprising at least one Amido-Substituted Heterocycle Compounds for treating or preventing a herpesvirus infection in a patient.
-
Patent Agency Ranking
公开(公告)号：US20230159592A1
公开(公告)日：2023-05-25
申请号：US17854379
申请日：2022-06-30
Applicant: Merck Sharp & Dohme LLC
Inventor： Harold B. Wood , Hubert B. Josien , Thomas Joseph Tucker , Angela Dawn Kerekes , Ling Tong , Abbas M. Walji , Anilkumar G. Nair , Fa-Xiang Ding , Elisabetta Bianchi , Danila Branca , Chengwei Wu , Yusheng Xiong , Sookhee Nicole HA , Jian Liu , Sobhana Babu Boga
Abstract: Disclosed are compounds of Formula I, or a salt thereof:
where A, B, D, X, R1, R2 and R8 are as defined herein, which compounds have properties for antagonizing PCSK9. Also described are pharmaceutical formulations comprising the compounds of Formula I or their salts, and methods of treating cardiovascular disease and conditions related to PCSK9 activity, e.g. atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions.-
7.发明授权公开(公告)号：US11970479B2
公开(公告)日：2024-04-30
申请号：US17286591
申请日：2019-10-24
Applicant: Merck Sharp & Dohme LLC , MSD R&D (China) Co. LTD.
Inventor： John J. Acton, III , Melissa Egbertson , Xiaolei Gao , Scott T. Harrison , Timothy J. Henderson , Michael Man-Chu Lo , Robert D. Mazzola, Jr. , Zhaoyang Meng , James Mulhearn , Vanessa L. Rada , Jeffrey W. Schubert , Oleg B. Selyutin , David M. Tellers , Ling Tong , Fengqi Zhang , Jianming Bao , Chunsing Li
IPC: C07D401/14 , C07D405/14
CPC classification number: C07D401/14 , C07D405/14
Abstract: The present invention is directed to cinnolinyl and quinolinyl pyrazol-4-yl-pyridine compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.
-
8.发明公开公开(公告)号：US20240067657A1
公开(公告)日：2024-02-29
申请号：US18258903
申请日：2021-12-21
Applicant: Kira A. ARMACOST , Richard Thaddeus BERGER , Andrew J. COOKE , Christopher Douglas COX , Brendan M. CROWLEY , Marc LABROLI , Michael Aaron PLOTKIN , Izzat Tiedje RAHEEM , Anthony W. SHAW , Kelly-Ann S. SCHLEGEL , Jason W. SKUDLAREK , Ling TONG , Merck Sharp & Dohme LLC
Inventor： Kira A. Armacost , Richard Thaddeus Berger, Jr. , Andrew J. Cooke , Christopher Douglas Cox , Brendan M. Crowley , Marc Labroli , Michael Aaron Plotkin , Izzat Tiedje Raheem , Anthony W. Shaw , Kelly-Ann S. Schlegel , Jason W. Skudlarek , Ling Tong
IPC: C07D498/04 , A61K31/517 , C07D401/12 , C07D401/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D519/00
CPC classification number: C07D498/04 , A61K31/517 , C07D401/12 , C07D401/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D519/00
Abstract: The present invention relates to novel Amido-Substituted Heterocycle Compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R7, and R8 are as defined herein. The present invention also relates to compositions comprising at least one Amido-Substituted Heterocycle Compound, and methods of using the Amido-Substituted Heterocycle Compounds for treating or preventing a herpesvirus infection in a patient.
-
9.发明公开公开(公告)号：US20240059693A1
公开(公告)日：2024-02-22
申请号：US18256997
申请日：2021-12-14
Applicant: Merck Sharp & Dohme LLC
Inventor： Ronald K. Chang , Andrew J. Cooke, JR. , Christopher Douglas Cox , Marc Labroli , Izzat Tiedje Raheem , Jack D. Scott , Jeffrey W. Schubert , Jason W. Skudlarek , Zheng Tan , Ling Tong
IPC: C07D487/04 , C07D519/00 , C07D403/14 , C07D403/06 , C07D413/14 , A61K31/517 , A61P31/22
CPC classification number: C07D487/04 , C07D519/00 , C07D403/14 , C07D403/06 , C07D413/14 , A61K31/517 , A61P31/22
Abstract: The present invention relates to novel Fused Bicyclic Pyrazole Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, and R6 are as defined herein. The present invention also relates to compositions comprising at least one Fused Bicyclic Pyrazole Derivative, and methods of using the Fused Bicyclic Pyrazole Derivatives for treating or preventing a herpesvirus infection in a patient.
-
10.发明申请公开(公告)号：US20230054782A1
公开(公告)日：2023-02-23
申请号：US17783810
申请日：2020-12-17
Applicant: Andrew John COOKE , Brendan M. CROWLEY , Marc A. LABROLI , Michael Aaron PLOTKIN , Izzat T. RAHEEM , Ling TONG , Deyou SHA , Merck Sharp & Dohme LLC
Inventor： Andrew John Cooke , Brendan M. Crowley , Marc A. Labroli , Michael Aaron Plotkin , Izzat T. Raheem , Ling Tong , Deyou Sha
IPC: C07D491/04 , C07D519/00 , C07D405/14 , C07D471/04
Abstract: The present invention relates to novel Bicyclic Heterocycle Compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein A, X, Y, Z, R1 R5, R6, and R7 are as defined herein. The present invention also relates to compositions comprising at least one Bicyclic Heterocycle Compound, and methods of using the Bicyclic Heterocycle Compounds for treating or preventing a herpesvirus infection in a patient.
-
-
-
-
-
-
-
-
-
Search Results
10
records
(took 0.018 seconds)
